EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer

Stephanie L Graff iD, Sara M Tolaney iD, Lowell L Hart, Pedram Razavi, Wolfgang Janni, Lee S Schwartzberg, Andriy Danyliv, Murat Akdere, Ilia Ferrusi, Rishi Rajat Adhikary, Joyce A O'Shaughnessy

Cancer · 2025

DOI: 10.1002/cncr.35817 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Stephanie L Graff und 10 weiteren Autor:innen. Beteiligte Einrichtung: Brown University Health Cancer Institute, Legorreta Cancer Center at Brown University, Providence, Rhode Island, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Novartis Pharmaceuticals Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Overall survival (OS) is the gold standard for assessing clinical benefit in oncology but requires extended follow‐up to detect sufficient events. Invasive disease‐free survival (iDFS) requires shorter follow‐up times and is considered an objective and clinically meaningful end point in early breast cancer (EBC) trials. The authors assessed iDFS as a surrogate end point for OS in adjuvant HR+/HER2– EBC using real‐world patient‐level data.

Methods

A retrospective analysis was conducted on patient data from the ConcertAI Patient360 database (January 1995–April 2021). Key inclusion criteria: age ≥18 years, stage II or III (AJCC 8th Edition) HR+/HER2– EBC, prior surgery, adjuvant endocrine therapy (ET). Spearman ρ, iterative multiple imputation ρ (IMI; 0.8–1 considered “very strong”), and R 2 (clinical relevance R 2 ≥ 0.70) were used to assess iDFS–OS relationship. Subgroup analyses included ET (nonsteroidal aromatase inhibitor or tamoxifen), stage, menopausal status, nodal status, prior (neo)adjuvant chemotherapy, and prior radiotherapy.

Results

A total of 3133 patients were included (1103 [35.2%] iDFS events; 554 [17.7%] OS events); mean age was 58.4 years, 98.8% were female, 29.9% were premenopausal, and 80.9% had stage II disease. Median follow‐up time was 55.1 months. iDFS and OS exhibited a positive, very strong, clinically relevant correlation (Spearman ρ: 0.88 [0.87–0.89]; IMI ρ: 0.83 [0.79–0.86]; both p < .0001). iDFS accounted for 82% of variation in OS (R 2 = 0.82). Results of all subgroup analyses were consistent with overall population.

Conclusions

This patient‐level real‐world analysis demonstrated very strong, positive correlations between iDFS and OS, supporting the use of iDFS as a reliable primary end point in adjuvant HR+/HER2– EBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansFemaleMiddle AgedRetrospective StudiesAgedDisease-Free SurvivalAdultChemotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneNeoplasm Staging

Stichwörter der Autor:innen

HR+/HER2– early breast cancercorrelation analysisinvasive disease‐free survivaloverall survivalreal world

Substanzen

Erb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, human

Autor:innen und Institutionen

  • Brown University Health Cancer Institute, Legorreta Cancer Center at Brown University, Providence, Rhode Island, USA.
  • Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Florida Cancer Specialists, Sarah Cannon Research Institute, Fort Myers, Florida, USA.
  • Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
  • Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.

ORCID-Profile: Stephanie L Graff, Sara M Tolaney

Förderung

  • NCI NIH HHS
  • Novartis Pharmaceuticals Corporation

Zitieren

APA

Graff, S. L., Tolaney, S. M., Hart, L. L., Razavi, P., Janni, W., Schwartzberg, L. S., Danyliv, A., Akdere, M., Ferrusi, I., Adhikary, R. R., & O'Shaughnessy, J. A. (2025). Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer. Cancer. https://doi.org/10.1002/cncr.35817

Vancouver

Graff SL, Tolaney SM, Hart LL, Razavi P, Janni W, Schwartzberg LS, et al. Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer. Cancer. 2025. doi:10.1002/cncr.35817

BibTeX
@article{Graff2025,
  author = {Graff, Stephanie L and Tolaney, Sara M and Hart, Lowell L and Razavi, Pedram and Janni, Wolfgang and Schwartzberg, Lee S and Danyliv, Andriy and Akdere, Murat and Ferrusi, Ilia and Adhikary, Rishi Rajat and O'Shaughnessy, Joyce A},
  title = {Correlation analysis of invasive disease‐free survival and overall survival in a real‐world population of patients with HR+/HER2– early breast cancer},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.35817}
}
Kostenlos starten →